While for most individuals, picking a restaurant to dine at could simply be based on what they might be craving at the moment, for about one to five per cent…
Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In this guide, we explore 15 interesting biotech companies in Paris. Paris is one of the…
Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its rival Aimmune. After recent talks with the FDA and EMA, DBV has laid out a…
As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector…
A request for market approval of a skin patch developed by French biotech DBV Technologies to treat peanut allergy has been turned down by the FDA, which has requested more…
French biotech DBV Technologies’ bid for the US approval of a skin patch to treat nut allergies could be delayed as the FDA requested more information on the patch’s efficacy.…
DBV Technologies has shown in a Phase II trial that its skin patch could desensitize over 60% of children with strong milk allergy. DBV Technologies, one of the largest public biotechs…
DBV Technologies' candidate could be the first treatment for allergies to cow milk after its Viaskin Milk skin patch achieved positive Phase II results. DBV Technologies is developing a skin…
DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy in children, though its efficacy is uncertain. DBV Technologies saw its stock go down by 45%…
DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of…
The first French biotech to NASDAQ, DBV, is expanding the patient group for its promising peanut allergy treatment to include toddlers. DBV Technologies' Phase IIb results of its peanut allergy therapy,…
Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what…
We had a look into European biotech and created a map with the biggest biotech companies in each country, according to their market cap. Biotech is one of the biggest…
What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here's a list of the best success stories of 2016. Biotech is becoming a…
DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff. DBV Technologies, the…
How annoying are needle vaccinations? Very ... But the French billion-euro Biotech DBV Technologies wants to bring a paradigm shift via its Anti-allergy Patch platform! I got to chat with…
Europe has a lot of successful Biotech companies, but which of those are worth a billion euros or more? I did a previous version of this article last year and now I explore how…
The billion-euro Biotech from Paris DBV Technologies just signed a €100M deal with Nestlé Health Science to develop a new diagnostic test of Milk allergies. This is the first deal…
DBV Technologies (Paris) was just under the spotlight in Los Angeles at the biggest allergy convention worldwide (2016 AAAAI Annual Meeting). Their Viaskin skin patch could potentially eradicate peanut allergies for patients altogether...…
Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock…